» Articles » PMID: 29900417

The Tatton-Brown-Rahman Syndrome: A Clinical Study of 55 Individuals with Constitutive Variants

Abstract

Tatton-Brown-Rahman syndrome (TBRS; OMIM 615879), also known as the DNMT3A-overgrowth syndrome, is an overgrowth intellectual disability syndrome first described in 2014 with a report of 13 individuals with constitutive heterozygous variants. Here we have undertaken a detailed clinical study of 55 individuals with variants, including the 13 previously reported individuals. An intellectual disability and overgrowth were reported in >80% of individuals with TBRS and were designated major clinical associations. Additional frequent clinical associations (reported in 20-80% individuals) included an evolving facial appearance with low-set, heavy, horizontal eyebrows and prominent upper central incisors; joint hypermobility (74%); obesity (weight ³2SD, 67%); hypotonia (54%); behavioural/psychiatric issues (most frequently autistic spectrum disorder, 51%); kyphoscoliosis (33%) and afebrile seizures (22%). One individual was diagnosed with acute myeloid leukaemia in teenage years. Based upon the results from this study, we present our current management for individuals with TBRS.

Citing Articles

Case Report: A case of Tatton-Brown-Rahman syndrome featuring mitral annular disjunction and mitral valve prolapse due to a novel mutation site in the gene.

Xu Z, Shen R, Hu W, Lv L, Shi Z, Lin L Front Cardiovasc Med. 2025; 11:1507318.

PMID: 39902084 PMC: 11788380. DOI: 10.3389/fcvm.2024.1507318.


The N-terminal region of DNMT3A engages the nucleosome surface to aid chromatin recruitment.

Wapenaar H, Clifford G, Rolls W, Pasquier M, Burdett H, Zhang Y EMBO Rep. 2024; 25(12):5743-5779.

PMID: 39528729 PMC: 11624362. DOI: 10.1038/s44319-024-00306-3.


Using human disease mutations to understand de novo DNA methyltransferase function.

Rolls W, Wilson M, Sproul D Biochem Soc Trans. 2024; 52(5):2059-2075.

PMID: 39446312 PMC: 11555716. DOI: 10.1042/BST20231017.


Recurrent carotid paragangliomas in a syndromic patient with a heterozygous missense variant in DNA Methyltransferase 3 Alpha.

German R, Vuocolo B, Vossaert L, Saba L, Fletcher R, Tedder M Am J Med Genet A. 2024; 197(1):e63849.

PMID: 39166703 PMC: 11637962. DOI: 10.1002/ajmg.a.63849.


From Environment to Gene Expression: Epigenetic Methylations and One-Carbon Metabolism in Amyotrophic Lateral Sclerosis.

Hernan-Godoy M, Rouaux C Cells. 2024; 13(11.

PMID: 38891099 PMC: 11171807. DOI: 10.3390/cells13110967.


References
1.
Ley T, Ding L, Walter M, McLellan M, Lamprecht T, Larson D . DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363(25):2424-33. PMC: 3201818. DOI: 10.1056/NEJMoa1005143. View

2.
Yan X, Xu J, Gu Z, Pan C, Lu G, Shen Y . Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011; 43(4):309-15. DOI: 10.1038/ng.788. View

3.
Nikoloski G, van der Reijden B, Jansen J . Mutations in epigenetic regulators in myelodysplastic syndromes. Int J Hematol. 2012; 95(1):8-16. DOI: 10.1007/s12185-011-0996-3. View

4.
Tatton-Brown K, Weksberg R . Molecular mechanisms of childhood overgrowth. Am J Med Genet C Semin Med Genet. 2013; 163C(2):71-5. DOI: 10.1002/ajmg.c.31362. View

5.
Abdel-Wahab O, Levine R . Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013; 121(18):3563-72. PMC: 3643757. DOI: 10.1182/blood-2013-01-451781. View